Episode 9. CAR-T cell therapy in Lymphoma
In this episode, we take a deep dive into CAR-T cell therapy in lymphoma with Dr. Frederick Locke from Moffitt Cancer Center and discuss the three key randomized phase 3 trials in 2nd line therapy by comparing CAR T-cell to the current standard of care.
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
- In this episode, we discussed the three CD19-directed chimeric antigen receptor (CAR T-cell) therapies that have been approved for relapsed/refractory aggressive large B cell lymphomas (LBCL) after two lines of therapy:
- Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447
- Tisagenlecleucel (tisa-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1804980
- Lisocabtagene maraleucel (lisocel)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31366-0/fulltext
2. Next, we delved into the three prospective phase 3 randomized clinical trials that were conducted to define the optimal second-line treatment by comparing each of the CAR T-cell products to the current standard of care
- ZUMA-7 for axicabtagene ciloleucel https://www.nejm.org/doi/full/10.1056/NEJMoa2116133
- BELINDA for tisagenlecleucel https://www.nejm.org/doi/full/10.1056/NEJMoa2116596
- TRANSFORM for lisocabtagene maraleucel https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00662-6/fulltext
3. Then, we briefly discussed the preliminary studies of CAR-T cell therapy in front-line therapy for large B cell lymphoma
- Axicabtagene ciloleucel (axi-cel) https://www.nature.com/articles/s41591-022-01731-4